MCRB - Seres Therapeutics, Inc.

QQQ $ 451.63 $ -0.22 (-0.05 %)

DIA $ 399.76 $ 0.74 (0.19 %)

SPY $ 529.24 $ 0.76 (0.14 %)

TLT $ 91.40 $ -0.62 (-0.67 %)

GLD $ 223.63 $ 3.63 (1.65 %)

Previous Close

$ 0.9199

Open

$ 0.93

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 0.91 - $ 0.99

52 Week Range

$ 0.54 - $ 6.26

Volume

2,009,826

Average Volume

Market Cap

134.4M

Beta (5Y Monthly)

$ 1.15

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-08-2024	03-31-2024	10-Q
2	03-05-2024	12-31-2023	10-K
3	11-02-2023	09-30-2023	10-Q
4	08-08-2023	06-30-2023	10-Q
5	05-09-2023	03-31-2023	10-Q
6	03-07-2023	12-31-2022	10-K
7	11-02-2022	09-30-2022	10-Q
8	08-03-2022	06-30-2022	10-Q
9	05-04-2022	03-31-2022	10-Q
10	03-01-2022	12-31-2021	10-K
11	11-10-2021	09-30-2021	10-Q
12	08-03-2021	06-30-2021	10-Q
13	05-04-2021	03-31-2021	10-Q
14	03-02-2021	12-31-2020	10-K
15	11-09-2020	09-30-2020	10-Q
16	07-28-2020	06-30-2020	10-Q
17	05-07-2020	03-31-2020	10-Q
18	03-02-2020	12-31-2019	10-K
19	11-05-2019	09-30-2019	10-Q
20	08-06-2019	06-30-2019	10-Q
21	05-02-2019	03-31-2019	10-Q
22	03-06-2019	12-31-2018	10-K
23	11-08-2018	09-30-2018	10-Q
24	08-02-2018	06-30-2018	10-Q
25	05-09-2018	03-31-2018	10-Q
26	03-08-2018	12-31-2017	10-K
27	11-08-2017	09-30-2017	10-Q
28	08-03-2017	06-30-2017	10-Q
29	05-04-2017	03-31-2017	10-Q
30	03-16-2017	12-31-2016	10-K
31	11-10-2016	09-30-2016	10-Q
32	08-11-2016	06-30-2016	10-Q
33	05-16-2016	03-31-2016	10-Q
34	03-14-2016	12-31-2015	10-K
35	11-12-2015	09-30-2015	10-Q
36	08-10-2015	06-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Oppenheimer Maintains Outperform on Seres ...
05/09/2024 16:50:17

Oppenheimer analyst Jeff Jones maintains Seres Therapeutics (NASDAQ:MCRB) with a Outperform and lowers the price target from...

12-health-care-stocks-moving-in-thursdays-intraday-session

12 Health Care Stocks Moving In Thursday's...
05/09/2024 16:31:09

why-upstart-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Why Upstart Shares Are Trading Lower By Ar...
05/08/2024 17:38:56

12-health-care-stocks-moving-in-wednesdays-intraday-session

12 Health Care Stocks Moving In Wednesday'...
05/08/2024 16:31:09

nasdaq-down-over-50-points-uber-posts-q1-loss

Nasdaq Down Over 50 Points; Uber Posts Q1 ...
05/08/2024 14:02:37

Seres Therapeutics' Q1 Cash And Cash Equiv...
05/08/2024 11:07:10

Seres Therapeutics Q1 2024 GAAP EPS $(0.27...
05/08/2024 11:05:53

Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(...

Seres Therapeutics Concludes Enrollment In...
04/09/2024 11:11:45

Seres Therapeutics Announced That On March...
03/28/2024 11:26:45

Oppenheimer Maintains Outperform on Seres ...
03/06/2024 13:59:45

Oppenheimer analyst Jeff Jones maintains Seres Therapeutics (NASDAQ:MCRB) with a Outperform and lowers the price target from...

emerson-electric-to-rally-more-than-19-here-are-10-top-analyst-forecasts-for-wednesday

Emerson Electric To Rally More Than 19%? H...
03/06/2024 13:00:40

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Chardan Capital Maintains Buy on Seres The...
03/06/2024 12:38:27

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and lowers the price target from $1...

Seres' $128M In Cash Balance, Planned Savi...
03/05/2024 12:07:11

Seres Therapeutics FY GAAP EPS $(0.89) Bea...
03/05/2024 12:04:40

Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate of $(...

Earnings Scheduled For March 5, 2024
03/05/2024 10:00:02

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...

Seres Therapeutics's Earnings: A Preview
03/04/2024 16:02:42

Seres Therapeutics Announced That Marella ...
02/26/2024 12:09:28

Seres Therapeutics Reports Inducement Gran...
01/17/2024 12:10:15

Seres Therapeutics, Inc. (NASDAQ:MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, t...

Oppenheimer Maintains Outperform on Seres ...
01/16/2024 15:37:32

Oppenheimer analyst Jeff Jones maintains Seres Therapeutics (NASDAQ:MCRB) with a Outperform and lowers the price target from...

why-is-microbiome-based-seres-therapeutics-stock-trading-higher-today

Why Is Microbiome-Based Seres Therapeutics...
01/09/2024 17:12:41

Seres Therapeutics Inc (NASDAQ: MCRB) received FDA Fast Track Designation for SER-155, an investigational oral, cultivated micr...